Últimas noticias sobre AbbVie (NYSE:ABBV) Bolsa

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

ABBV

CHWY

RIVN

ULTA

Descubre las acciones con mayor potencial en 2025 en belleza, salud y tecnología. ¿Qué estrategias impulsan su éxito?

Wall Street revela 4 acciones prometedoras: Sectores clave para invertir en 2025

AbbVie Inc

Former U.S. Secretary of Labor Robert Reich has called out the tax reduction plans of the Donald Trump-led administration in an X post, terming them as an &#8220;absolutely shameless giveaway,&#8221; that could shoot up the deficit by $4.6 trillion.
What Happened: The possible tax cuts for rich individuals and lower corporate tax rates are likely to widen the U.S. trade deficit, which the Trump 2.0 administration would most likely fund from the tariffs imposed on its trading partners.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Trump wants to extend his tax cuts for rich individuals, which would add $4.6T to the deficit. But he wants to go even further, cutting the corporate tax rate to 15%. It&#39;s yet another absolutely shameless giveaway. <a href="https://t.co/mkAWOFkkUd">pic.twitter.com/mkAWOFkkUd</a>
&mdash; Robert Reich (@RBReich) <a href="https://twitter.com/RBReich/status/1891623719304339516?ref_src=twsrc%5Etfw">February 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The data from the Center For American Progress Action Fund or CAPAF shows that cutting the corporate tax rate down to 15% would save all sectors and companies billions of dollars in tax.
<ul>
<li>Top 100 U.S. Companies: Can expect a total annual tax cut of $48 billion despite reporting $1.1 trillion in profits in their 2023 annual report.</li>
</ul>
<ul>
<li>Top 10 U.S. Companies: Reported more than $520 billion in profits according to their 2023 annual report can expect an annual tax cut of $23 billion. These include firms like Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Comcast Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), and JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>).</li>
</ul>
<ul>
<li>Oil: The five largest U.S. oil companies, including Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>), Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>), and Valero Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) will receive an estimated $2.2 billion annual tax cut, despite over $80 billion in profits.</li>
</ul>
<ul>
<li>Pharma: The five largest U.S. drug makers, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) will receive an estimated $3.1 billion annual tax cut, despite over $50 billion in profits.</li>
</ul>
<ul>
<li>Banking: The five largest Wall Street banks, JPMorgan Chase, Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) and Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) will receive an estimated $4.1 billion annual tax cut, despite nearly $113 billion in profits.</li>
</ul>
<ul>
<li>Grocery: The five largest grocery companies, Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), Albertsons Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>), Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) will receive an estimated $1.7 billion annual tax cut, despite over $29 billion in profits.</li>
</ul>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43763438/trump-acting-like-a-mafia-don-says-this-economist-as-uncertainty-mounts-businesses-hold-back-in-fear-of-unforeseen-economic-shifts">Trump &#8216;Acting Like A Mafia Don,&#8217; Says This Economist As Uncertainty Mounts, Businesses Hold Back In Fear Of Unforeseen Economic Shifts</a>
Why It Matters: Trump has threatened all its trading partners with &#8220;reciprocal tariffs,&#8221; while already having implemented 25% on steel and aluminum imports.
According to economists like Craig Shapiro, who is a macro strategist at the Bear Traps Report, tariffs are the "<a href="https://www.benzinga.com/25/02/43587245/tariffs-are-the-only-way-to-fund-tax-cuts-without-deficit-expansion-argues-expert-as-it-takes-center-stage-in-donald-trumps-economic-plan">only way</a>" to fund tax cuts without expanding the federal deficit. 
Shapiro likened Trump&#8217;s governance to that of a &#8220;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43763438/trump-acting-like-a-mafia-don-says-this-economist-as-uncertainty-mounts-businesses-hold-back-in-fear-of-unforeseen-economic-shifts">Mafia Don</a>,&#8221; saying businesses are now uncertain about the economy&#8217;s direction. He noted fading &#8220;initial euphoria&#8221; and a &#8220;wait-and-see&#8221; approach from business leaders due to unclear policies, tariffs, trade agreement uncertainty, and fluctuating government spending. &#8211;
Price Action: On Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) which track the S&amp;P 500 and Nasdaq 100 indices, closed mixed. SPY fell 0.0049% to a value of $609.7, and QQQ was up by 0.42% to end at a value of $538.15, according to Benzinga Pro data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43773441/ahead-of-gamestops-bitcoin-purchase-plans-blackrock-morgan-stanley-goldman-sachs-and-other-billion-dollar-funds-load-up-on-gme-stock-in-q4">Ahead Of GameStop&#8217;s Bitcoin Purchase Plans, BlackRock, Morgan Stanley, Goldman Sachs, And Other Billion Dollar Funds Load Up On GME Stock In Q4</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Macro Notification

News

Economics

Markets

CMCSA

COST

Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich

AbbVie's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) short percent of float has risen 3.88% since its last report. The company recently reported that it has 18.93 million shares sold short, which is 1.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AbbVie Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739813412_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AbbVie has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing AbbVie's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AbbVie's peer group average for short interest as a percentage of float is 5.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About AbbVie?

Management

AbbVie Board Elected Robert A. Michael To Succeed Richard A. Gonzalez As Chairman

On Wednesday,&nbsp;AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)&nbsp;and Xilio Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43654121/abbvie-and-xilio-therapeutics-announce-collaboration-and-option-agreement-to-develop-novel-tumor-a" rel="noreferrer noopener">leveraging Xilio&#8217;s proprietary technology</a>.
Xilio has developed a proprietary, clinically validated platform technology for tumor-activated biologics.
The company is advancing a pipeline of clinical and preclinical immunotherapies, including masked multispecific molecules, designed to achieve tumor-selective activation by leveraging masking and other unique components that are optimized for the specific target.
The action allows focused activity within the tumor microenvironment to minimize systemic adverse events.
Under the terms of the agreement, Xilio will receive $52.0 million in upfront payments, including a $10 million equity investment, and will be eligible to receive up to approximately $2.1 billion in contingent payments for option-related fees and milestones plus tiered royalties.
Concurrently, Xilio Therapeutics announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen for prostate cancer (PSMA), claudin 18.2 (CLDN18.2) and six-transmembrane epithelial <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43654150/xilio-therapeutics-announces-multiple-masked-t-cell-engager-programs" rel="noreferrer noopener">antigen of prostate 1 (STEAP1)</a>.
<ul>
<li>Xilio anticipates nominating a development candidate for its PSMA program in the ATACR format in the third quarter of 2025 and submitting an investigational new drug application (IND) in the first quarter of 2027.</li>
<li>CLDN18.2 has broad potential as a T cell engager target for gastric, pancreatic, esophageal, and lung cancers. Xilio anticipates nominating a development candidate for its CLDN18.2 program in the ATACR format in the fourth quarter of 2025 and submitting an IND in the second quarter of 2027.</li>
<li>STEAP1 has broad potential as a T cell engager target for prostate, colorectal, and lung cancers. Xilio anticipates nominating a development candidate for its STEAP1 program in the SEECR format in the first half of 2026 and submitting an IND in the second half of 2027.</li>
</ul>
Xilio anticipates that its existing cash and cash equivalents and the upfront payments under the agreement with AbbVie will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2026.
Price Action: XLO stock is up 116.10% at $1.42 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43658118/martin-marietta-increases-revenue-expands-margins-ceo-expects-data-center-demand-to-offset-ongoing-softness" target="_blank" rel="noreferrer noopener">Martin Marietta Increases Revenue, Expands Margins: CEO Expects &#8216;Data Center Demand To Offset Ongoing Softness&#8217;</a></li>
</ul>

Biotech

Health Care

Contracts

Movers

General

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

AbbVie And Xilio Therapeutics Announced A Collaboration And Option-to-license Agreement To Develop Novel Tumor-activated, Antibody-based Immunotherapies, As Per Which Xilio Will Receive $52.0M In Total Upfront Payments And Be Eligible To Receive Up To Around $2.1B In Total Contingent Payments For Option-related Fees And Milestones Plus Tiered Royalties

<ul>
<li>EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria</li>
<li>Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies</li>
<li>Antimicrobial resistance (AMR) could lead to over 39 million deaths worldwide by 2050, and new treatments are urgently needed1</li>
</ul>
NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO&#x2122;&nbsp;(aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. It is approved in combination with metronidazole, for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI), including those caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens. Approval of this indication is based on limited clinical safety and efficacy data for EMBLAVEO. Gram-negative bacterial infections are among the most challenging for healthcare professionals to control due to high antimicrobial resistance (AMR).2 When AMR develops, medicines intended to treat these infections become ineffective, increasing the risk of morbidity and mortality.2

U.S. FDA Approves EMBLAVEO For The Treatment Of Adults With Complicated Intra-Abdominal Infections With Limited Or No Treatment Options

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), saying it's &#8220;just a gem&#8221; and a &#8220;winner.&#8221; &nbsp;He added, &#8220;I can't believe the stock dropped so much.&#8221;
On Jan. 31, AbbVie reported fourth-quarter adjusted earnings per share of $2.16, beating the street view of $2.11. Quarterly sales of $15.102 billion, outpacing the analyst consensus estimate of $14.827 billion. Several analysts also raised their price targets on the stock following the earnings announcement.
<h3 class="wp-block-heading">Cramer Shares His Views On These Tech Stocks</h3>
MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) is a trade and not an investment, Cramer said. &#8220;You'd be catching it at the right time. I think the analysts are all starting to upgrade the, the enterprise software again. I think it's worth a stab, I really do.&#8221;
In the recent news, MongoDB has partnered with Lombard Odier to modernize core banking technology with generative AI.
The Mad Money host recommended pulling the trigger on Cerence Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>).
On the earnings front, Cerence is scheduled to announce its first quarter financial results on Thursday, Feb. 6.
<h3 class="wp-block-heading">Other Stocks In Focus</h3>
Cramer recommended buying Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) instead of going with Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>).
Supporting his view, Keefe, Bruyette &amp; Woods analyst Kyle Voigt, on Jan. 13, maintained Coinbase with a Market Perform and lowered the price target from $275 to $255.
Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) is the better one, Cramer said when asked about Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>). &#8220;If you want AI, then you go with Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>).&#8221;
Supporting that view, Loop Capital analyst Mark Schappel, on Jan. 14, maintained Tempus AI with a Buy and lowered the price target from $57 to $52.
Price Action:
<ul>
<li>MongoDB shares gained 2.7% to settle at $275.97 on Tuesday.</li>
<li>Tempus shares gained 0.5% to close at $61.85 during the session.</li>
<li>Coinbase shares fell 1.4% to settle at $280.39.</li>
<li>AbbVie shares fell 0.1% to close at $189.95 on Tuesday.</li>
<li>Cerence shares gained 6.2% to settle at $12.07.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Long Ideas

Media

$BTC

COIN

CRNC

Jim Cramer: This Health Care Stock Is A 'Winner,' Buy Bitcoin Instead Of Coinbase

Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and raises the price target from $205 to $215.

Price Target

Analyst Ratings

Citigroup Maintains Buy on AbbVie, Raises Price Target to $215

Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 24 uncommon options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 50%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $105,465, and 21 are calls, for a total amount of $1,655,712.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $210.0 for AbbVie over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AbbVie's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale trades within a strike price range from $150.0 to $210.0 in the last 30 days. 
<h3>AbbVie Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738607428_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.7</td>
<td>$4.55</td>
<td>$4.56</td>
<td>$195.00</td>
<td>$615.5K</td>
<td align="right">546</td>
<td>1.4K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$15.5</td>
<td>$14.2</td>
<td>$15.3</td>
<td>$175.00</td>
<td>$84.1K</td>
<td align="right">225</td>
<td>171</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$16.1</td>
<td>$14.6</td>
<td>$15.15</td>
<td>$175.00</td>
<td>$83.3K</td>
<td align="right">225</td>
<td>61</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$10.9</td>
<td>$10.1</td>
<td>$10.1</td>
<td>$180.00</td>
<td>$77.7K</td>
<td align="right">529</td>
<td>22</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/07/25</td>
<td>$16.85</td>
<td>$16.2</td>
<td>$16.58</td>
<td>$172.50</td>
<td>$72.9K</td>
<td align="right">200</td>
<td>45</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Following our analysis of the options activities associated with AbbVie, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>Trading volume stands at 4,545,253, with ABBV's price up by 3.15%, positioned at $189.7.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 81 days.</li>
</ul>
<h3>What Analysts Are Saying About AbbVie</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $208.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Raymond James has revised its rating downward to Outperform, adjusting the price target to $220. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on AbbVie with a target price of $190. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on AbbVie, which currently sits at a price target of $211. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on AbbVie, which currently sits at a price target of $205. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on AbbVie with a target price of $217. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Looking At AbbVie's Recent Unusual Options Activity

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>UBS cut Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) price target from $114 to $107. UBS analyst Lloyd Walmsley maintained a Buy rating. Uber shares closed at $66.85 on Friday. <a href="https://www.benzinga.com/quote/UBER/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities raised the price target for AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) from $211 to $217. Truist Securities analyst Srikripa Devarakonda maintained a Buy rating. AbbVie shares closed at $183.90 on Friday. <a href="https://www.benzinga.com/quote/ABBV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) price target from $245 to $370. Goldman Sachs analyst Kash Rangan maintained a Buy rating. Atlassian shares closed at $306.78 on Friday. <a href="https://www.benzinga.com/quote/TEAM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods raised the price target for Trustmark Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) from $45 to $47. Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintained an Outperform rating. Trustmark shares closed at $37.50 on Friday. <a href="https://www.benzinga.com/quote/TRMK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Susquehanna raised the price target for Baker Hughes Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) from $53 to $55. Susquehanna analyst Charles Minervino maintained a Positive rating. Baker Hughes shares closed at $46.18 on Friday. <a href="https://www.benzinga.com/quote/BKR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel cut e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) price target from $115 to $105. Stifel analyst Mark Astrachan maintained a Hold rating. e.l.f. Beauty shares settled at $99.91 on Friday. <a href="https://www.benzinga.com/quote/ELF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group raised Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) price target from $74 to $83. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. Tapestry shares closed at $72.94 on Friday. <a href="https://www.benzinga.com/quote/TPR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird increased CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) price target from $390 to $430. Baird analyst Shrenik Kothari downgraded the stock from Outperform to Neutral. CrowdStrike shares closed at $398.07 on Friday.  <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised the price target for CarMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) from $98 to $101. Needham analyst Chris Pierce maintained a Buy rating. UPS shares settled at $85.64 on Friday. <a href="https://www.benzinga.com/quote/KMX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital increased NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) price target from $92 to $95. BMO Capital analyst Simeon Siegel maintained an Outperform rating. Nike shares closed at $76.90 on Friday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

CRWD

TEAM

TRMK

UBER

Nike To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday

Truist Securities analyst Srikripa Devarakonda maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and raises the price target from $211 to $217.

Truist Securities Maintains Buy on AbbVie, Raises Price Target to $217

UBS analyst Navin Jacob maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Neutral and raises the price target from $181 to $190.

UBS Maintains Neutral on AbbVie, Raises Price Target to $190

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Overweight and raises the price target from $195 to $210.

Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $210

WIIM

AbbVie shares are trading higher after multiple firms raised their respective price targets on the stock.

Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Overweight and raises the price target from $224 to $239.

Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $239

Raymond James analyst Gary Nachman reiterates AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Outperform and raises the price target from $218 to $220.

Reiteration

Raymond James Reiterates Outperform on AbbVie, Raises Price Target to $220

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and raises the price target from $212 to $214.

Guggenheim Maintains Buy on AbbVie, Raises Price Target to $214

BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Outperform and raises the price target from $208 to $215.

BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $215

Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program <a target="_blank" href="https://www.benzinga.com/25/01/43294006/trump-white-house-blames-outage-for-medicaid-website-lockout-we-have-confirmed-no-payments-have-been-affected" rel="noreferrer noopener">are key focus areas for potential healthcare reforms.</a>
Goldman Sachs analyst Salveen Richter, however, warns that federal Medicaid cuts could lead to stricter policies and lower drug coverage.
Per Richter, the 340B program is currently facing increased scrutiny, with proposed reforms that could potentially benefit biopharma companies by limiting eligibility for drug discounts, which would enable &#8220;transfer of profits&#8221; from providers back to biopharma.
This shift could positively impact major biopharma companies with high exposure to 340B drugs, such as Merck &amp; Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) and Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
However, the specifics of these reforms are still uncertain, which could cause &#8220;volatility&#8221; in the healthcare sector until more details are released.
At the same time, Medicaid funding and eligibility changes are under consideration as potential cost-saving measures by the new administration.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43392796/abbvie-jumps-after-q4-earnings-beat-skyrizi-and-rinvoq-boom-offsets-humira-decline" rel="noreferrer noopener">AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline</a>
These changes could have negative effects on biopharma companies with significant Medicaid drug exposure, including AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Gilead Sciences, and Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), whose top Medicaid drugs make up a large percentage of their US sales.
Overall, for the 340B program, the analyst sees potential policy/legal outcomes that would move dynamics towards a transfer of profits from providers to biopharma companies as a positive for much of the biopharma sector.
Meanwhile, potential Medicaid changes could create &#8220;potential headwinds&#8221; for healthcare providers and biopharma companies, though the exact effects remain uncertain.
The healthcare industry is awaiting further clarity on these proposed policy changes and their implications.
Overall, the analyst notes that exposure to Medicaid and 340B can vary widely by product and indication.
The top three highest-spend drugs for Medicaid (as of 2022) are AbbVie&#8217;s Humira, Gilead&#8217;s Biktarvy and Eli Lilly&#8217;s Trulicity for type 2 diabetes and cardiovascular disease.
For these drugs, Medicaid and 340B spending represented ~15-30% of the drugs' FY22 and FY23 revenue.
Further, 340B impact may vary for different methods of administration within the same indication &#8211; for example, Gilead&#8217;s expects lower 340B exposure for injectables for PrEP than for daily orals &#8211; and expansion of eligibility for 340B discounts may have an outsized impact on certain therapeutics over others.
Overall, 340B reform would serve as a tailwind to biopharma, as the aforementioned initiatives are generally intended to limit access to the statutory discount.
On the other hand, spending cuts to Medicaid could have a negative impact to volume if they have the effect of reducing coverage, the analyst writes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43308041/chevron-ge-vernova-engine-no-1-bet-big-on-ai-power-but-is-it-too-late" target="_blank" rel="noreferrer noopener">Chevron, GE Vernova Bet Big On AI Power: Data Centers To Consume Enough Natural Gas To Power 3.5 Million Homes</a></li>
</ul>

GILD

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts

Major stock indices have completed their recovery following Monday's sharp drop, buoyed by tech stocks rallying on the back of solid earnings <a href="https://www.benzinga.com/news/econ-s">and positive macroeconomic data.</a>
The S&amp;P 500 index stands at 6,118 points at midday trading in New York, not far from the all-time high of 6,128 points reached last Friday.
The Personal Consumption Expenditure price index — the Fed's preferred inflation gauge — <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43390001/feds-favorite-inflation-gauge-rises-as-predicted-consumer-spending-jumps-at-fastest-pace-in-9-months">came in line with expectations in December</a>, easing market participants&#8217; concerns over interest rates. Fed futures continue to reflect expectations for two rate cuts by the end of the year.
Meanwhile, personal spending posted a robust 0.7% increase in December, signaling strong consumer appetite in the final month of the year — a promising sign for corporate earnings.
The Magnificent Seven — as tracked by the Roundhill Magnificent Seven ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NASDAQ">MAGS</a>) – soared 1.6% on Friday, effectively erasing weekly losses after plunging as much as 3.1% on Monday due to the DeepSeek selloff.
Yet, within the elite group, NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) remains 12% lower than last Friday's close, with Friday&#8217;s gains primarily driven by Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
The Dow Jones, flat on the day, attempted to break its all-time highs at the open but faced resistance from sellers. Sector-wise, tech leads the charge, while energy lags following mixed earnings results from oil giants Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>).
Gold climbed above $2,800 per ounce, extending new records as demand for the ultimate safe-haven asset surges amid rising geopolitical and trade risks. This comes after President Donald Trump confirmed on Thursday his plan to introduce 25% tariffs on Mexico and Canada starting Feb. 1.
WTI crude oil prices were down 0.3% at $72.3 per barrel, potentially marking their second consecutive weekly decline.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) paused for a breather, holding steady at $104,800.
<h1 class="wp-block-heading">Friday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>• Nasdaq 100</td>
<td>21,814.96</td>
<td>1.4%</td>
</tr>
<tr>
<td>• S&amp;P 500</td>
<td>6,118.40</td>
<td>0.8%</td>
</tr>
<tr>
<td>• Russell 2000</td>
<td>2,315.94</td>
<td>0.4%</td>
</tr>
<tr>
<td>• Dow Jones</td>
<td>44,973.98</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:24 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013125&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.7% to $609.38.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) edged up by 0.1% to $449.30.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 1.4% to $530.49.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.5% to $229.68.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 1.2%; the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.7%.</li>
</ul>
<h2 class="wp-block-heading">Friday&#8217;s Stock Movers</h2>
<ul>
<li>Stocks reacting to earning reports included:
<ul>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), up 0.72%</li>
<li>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) up 0.80%</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) up 0.17% </li>
<li>KLA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) up 2.11%, </li>
<li>PPG Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) down 6.12%, </li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) down 6.36%, </li>
<li>Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) up 5.52%, </li>
<li>Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) down 16.5%,</li>
<li>LPL Financial Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) up 1.99%.</li>
<li>Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>): down 1.31%</li>
<li>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>): up 6.7%</li>
<li>Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): down 3.7%</li>
<li>Colgate-Palmolive Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>): down 4.5%</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>): down 0.8%</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>): up 3.6%</li>
<li>Booz Allen Hamilton Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>): down 0.6%</li>
</ul>
</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43398182/trumps-25-tariffs-could-slaughter-canada-mexico-economies-hit-us-auto-industry-analysts-warn">Trump&#8217;s 25% Tariffs Could Slaughter Canada, Mexico Economies, Hit US Auto Industry, Analysts Warn</a></li>
</ul>
Photo: Shutterstock

Earnings

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Econ #s

Tech

ETFs

AAPL

AMZN

CHTR

DECK

SPDR Dow Jones Industrial Average ETF Trust

INTC

KLAC

LPLA

MAGS

NVDA

TSLA

Tech Stocks Rally, S&P 500 Flirts With Records, Gold Extends All-Time Highs: What's Driving Markets Friday?

Press Releases

Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans

AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results

Allergan Aesthetics, the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society Release Two New Engaging LIMITLESS Videos Celebrating Women Surgeons

Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign

U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training

Dividends

AbbVie Declares Quarterly Dividend

AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Citigroup

Truist Securities

Wells Fargo

Morgan Stanley

Screenshot 2024-11-13 at 11.54.41 PM

TNXP

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-05-14 at 6.27.53 PM

BRTX

CYNO

BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

Screenshot 2024-02-24 at 12.03.42 AM

AXSM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Comments

AbbVie

Noticias

Últimas noticias sobre AbbVie (NYSE:ABBV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL